Randomized, Double-blinded, Placebo Controlled Study to Assess Efficacy of Oral 35 mg Per Week Risedronate in Preventing Bone Loss in Postmenopausal Women With Aromatase Inhibitor Therapy for Breast Cancer. [ESSAI RANDOMISE, EN DOUBLE AVEUGLE CONTRE PLACEBO EVALUANT L'EFFICACITE DU RISEDRONATE ORAL 35 MG PAR SEMAINE DANS LA PREVENTION DE LA PERTE OSSEUSE CHEZ LA FEMME ATTEINTE D'UN CANCER DU SEIN TRAITE PAR INHIBITEURS DE L'AROMATASE]

Trial Profile

Randomized, Double-blinded, Placebo Controlled Study to Assess Efficacy of Oral 35 mg Per Week Risedronate in Preventing Bone Loss in Postmenopausal Women With Aromatase Inhibitor Therapy for Breast Cancer. [ESSAI RANDOMISE, EN DOUBLE AVEUGLE CONTRE PLACEBO EVALUANT L'EFFICACITE DU RISEDRONATE ORAL 35 MG PAR SEMAINE DANS LA PREVENTION DE LA PERTE OSSEUSE CHEZ LA FEMME ATTEINTE D'UN CANCER DU SEIN TRAITE PAR INHIBITEURS DE L'AROMATASE]

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2013

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Osteoporosis
  • Focus Therapeutic Use
  • Acronyms RISAROS
  • Most Recent Events

    • 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Sep 2013 Status changed from recruiting to active, no longer recruiting., as reported by ClinicalTrials.gov record.
    • 10 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top